Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis.
Sonnenkalb L, Carter JJ, Spitaleri A, Iqbal Z, Hunt M, Malone KM, Utpatel C, Cirillo DM, Rodrigues C, Nilgiriwala KS, Fowler PW, Merker M, Niemann S; Comprehensive Resistance Prediction for Tuberculosis: an International Consortium. Sonnenkalb L, et al. Lancet Microbe. 2023 May;4(5):e358-e368. doi: 10.1016/S2666-5247(23)00002-2. Epub 2023 Mar 29. Lancet Microbe. 2023. PMID: 37003285 Free PMC article.
Mycobacterium tuberculosis complex whole-genome sequencing in New York State: Implementation of a reduced phenotypic drug susceptibility testing algorithm.
Shea J, Halse TA, Modestil H, Kearns C, Fowler RC, Da Costa-Carter CA, Siemetzki-Kapoor U, Leisner M, Lapierre P, Kohlerschmidt D, Rowlinson MC, Escuyer V, Musser KA. Shea J, et al. Among authors: escuyer v. Tuberculosis (Edinb). 2023 Sep;142:102380. doi: 10.1016/j.tube.2023.102380. Epub 2023 Jul 22. Tuberculosis (Edinb). 2023. PMID: 37543009 Free article.
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.
Haley CA, Schechter MC, Ashkin D, Peloquin CA, Peter Cegielski J, Andrino BB, Burgos M, Caloia LA, Chen L, Colon-Semidey A, DeSilva MB, Dhanireddy S, Dorman SE, Dworkin FF, Hammond-Epstein H, Easton AV, Gaensbauer JT, Ghassemieh B, Gomez ME, Horne D, Jasuja S, Jones BA, Kaplan LJ, Khan AE, Kracen E, Labuda S, Landers KM, Lardizabal AA, Lasley MT, Letzer DM, Lopes VK, Lubelchek RJ, Patricia Macias C, Mihalyov A, Misch EA, Murray JA, Narita M, Nilsen DM, Ninneman MJ, Ogawa L, Oladele A, Overman M, Ray SM, Ritger KA, Rowlinson MC, Sabuwala N, Schiller TM, Schwartz LE, Spitters C, Thomson DB, Tresgallo RR, Valois P, Goswami ND; BPaL Implementation Group. Haley CA, et al. Clin Infect Dis. 2023 Oct 5;77(7):1053-1062. doi: 10.1093/cid/ciad312. Clin Infect Dis. 2023. PMID: 37249079 Free PMC article.
High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
Dreyer V, Mandal A, Dev P, Merker M, Barilar I, Utpatel C, Nilgiriwala K, Rodrigues C, Crook DW; CRyPTIC Consortium; Rasigade JP, Wirth T, Mistry N, Niemann S. Dreyer V, et al. Genome Med. 2022 Aug 22;14(1):95. doi: 10.1186/s13073-022-01076-0. Genome Med. 2022. PMID: 35989319 Free PMC article.
Novel Mycobacterium tuberculosis Complex Genotype Related to M. caprae.
Shea J, Smith C, Halse TA, Kohlerschmidt D, Rourke AK, Musser KA, Escuyer V, Lapierre P. Shea J, et al. Among authors: escuyer v. Emerg Infect Dis. 2022 Jul;28(7):1431-1436. doi: 10.3201/eid2807.212353. Emerg Infect Dis. 2022. PMID: 35731170 Free PMC article.
50 results